AR081209A1 - TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11 - Google Patents

TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11

Info

Publication number
AR081209A1
AR081209A1 ARP110101725A ARP110101725A AR081209A1 AR 081209 A1 AR081209 A1 AR 081209A1 AR P110101725 A ARP110101725 A AR P110101725A AR P110101725 A ARP110101725 A AR P110101725A AR 081209 A1 AR081209 A1 AR 081209A1
Authority
AR
Argentina
Prior art keywords
bcl2l11
bcl2
natural
antisentide
transcript
Prior art date
Application number
ARP110101725A
Other languages
Spanish (es)
Original Assignee
Opko Curna Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Curna Llc filed Critical Opko Curna Llc
Publication of AR081209A1 publication Critical patent/AR081209A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

También se refiere a la identificación de estos oligonucleótidos antisentido y su uso para tratar enfermedades y trastornos asociados con la expresión de BCL2L11, tales como cáncer, apoptosis aberrante, enfermedad o trastorno proliferativo o de inmunidad deteriorada. Reivindicación 1: Un método de modular una función de y/o la expresión de un polinucleótido tipo BCL2 11 (BCL2L11) en un sistema biológico que comprende: poner en contacto dicho sistema con al menos un oligonucleótido antisentido de 5 a 30 nucleótidos de longitud en donde dicho al menos un oligonucleótido tiene al menos 50% de identidad de secuencia con un complemento inverso de un antisentido natural de un polinucleótido tipo BCL2 11 (BCL2L11); de este modo modula una función de y/o la expresión del polinucleótido tipo BCL2 11 (BCL2L11).It also refers to the identification of these antisense oligonucleotides and their use to treat diseases and disorders associated with the expression of BCL2L11, such as cancer, aberrant apoptosis, proliferative disease or disorder or impaired immunity. Claim 1: A method of modulating a function of and / or the expression of a polynucleotide type BCL2 11 (BCL2L11) in a biological system comprising: contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length in wherein said at least one oligonucleotide has at least 50% sequence identity with a reverse complement of a natural antisense of a BCL2 11 polynucleotide (BCL2L11); in this way it modulates a function of and / or the expression of the polynucleotide type BCL2 11 (BCL2L11).

ARP110101725A 2010-05-19 2011-05-19 TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11 AR081209A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34625210P 2010-05-19 2010-05-19

Publications (1)

Publication Number Publication Date
AR081209A1 true AR081209A1 (en) 2012-07-04

Family

ID=44992328

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101725A AR081209A1 (en) 2010-05-19 2011-05-19 TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11

Country Status (3)

Country Link
AR (1) AR081209A1 (en)
TW (1) TW201201819A (en)
WO (1) WO2011146674A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AU2013262649A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
WO2013173599A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
KR102028784B1 (en) 2012-05-16 2019-10-04 트랜슬레이트 바이오 인코포레이티드 Compositions and methods for modulating gene expression
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
WO2018085198A1 (en) 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
WO2020007702A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11

Also Published As

Publication number Publication date
WO2011146674A3 (en) 2012-04-05
WO2011146674A2 (en) 2011-11-24
TW201201819A (en) 2012-01-16

Similar Documents

Publication Publication Date Title
AR081209A1 (en) TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11
AR081993A1 (en) TREATMENT OF DISEASES RELATED TO THE SUBUNITY TO REGULATED BY VOLTAGE OF THE SODIUM CHANNEL (SCNA) BY INHIBITION OF THE SCNA ANTISENTIDO NATURAL TRANSCRIPT
AR081420A1 (en) TREATMENT OF DISEASES RELATED TO ATONAL HOMOLOGY 1 (ATOH1) THROUGH THE INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPTION FOR ATOH1
CY1118105T1 (en) VASCULAR USE OF CUTTY STEM CELLS
NZ737757A (en) Peptide oligonucleotide conjugates
EA201591281A1 (en) RIBONUCLEIC ACIDS WITH 4'-THIOMODIFIED NUCLEOTIDES AND RELATED METHODS
MX358603B (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene.
MX2011009752A (en) Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1.
WO2010129746A3 (en) Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
EA201490563A1 (en) ANTI-SMALL OLIGONUCLEOTIDE FOR THE TREATMENT OF CONGENITAL LEAVER AMAUROSIS
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
MX2011009751A (en) Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
BR112021024463A2 (en) Oligonucleotides and methods of use for the treatment of neurological diseases
BR112014027981A2 (en) fumagilol type compounds and methods of production and use thereof
BR112022023025A2 (en) HTT MODULATORS TO TREAT HUNTINGTON'S DISEASE
BR112021016613A2 (en) Agent capable of inhibiting signaling mediated by interleukin 11 (il-11), use of this in the manufacture of a medicine and methods
CY1123639T1 (en) MONOCLON OLIGONUCLEOTIDES FOR USE IN THE MEDICAL THERAPEUTIC TREATMENT OF SKIN DISORDERS
EA201791471A1 (en) METHODS OF APPLICATION OF ANTI-SMART OLIGONUCLEOTIDE SMAD7
AR092736A1 (en) PHARMACEUTICAL COMBINATIONS THAT INCLUDE DUAL BINDERS OF ANGIOPOYETINA-2 / DLL4 AND ANTI-VEGF-R AGENTS
BR112022006476A2 (en) OLIGONUCLEOTIDES WITH NUCLEOSID ANALOGS
ES2536640T3 (en) Targeted alteration of DNA with oligonucleotides
BR112018070249A2 (en) tissue specific expression modified u6 promoter system
MX2018007307A (en) Peptide oligonucleotide conjugates.
CO6660456A2 (en) Preventive or therapeutic agent against fibrosis
BR112015022308A8 (en) antisense oligonucleotides for the treatment of cancer stem cells

Legal Events

Date Code Title Description
FB Suspension of granting procedure